3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Lung Neoplasms
22
Carcinoma, Non-Small-Cell Lung
15
Ovarian Neoplasms
12
Fallopian Tube Neoplasms
11
Carcinoma, Hepatocellular
9
Colorectal Neoplasms
8
Urinary Bladder Neoplasms
7
Pancreatic Neoplasms
7
Melanoma
6
Lymphoma, Large B-Cell, Diffuse
6
Mycosis Fungoides
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Carcinoma, Renal Cell
5
Squamous Cell Carcinoma of Head and Neck
4
Neoplasm Metastasis
4
Lymphoma, T-Cell, Cutaneous
4
Glioblastoma
4
Colonic Neoplasms
4
Breast Neoplasms
4
Triple Negative Breast Neoplasms
3
Thyroid Neoplasms
3
Sezary Syndrome
3
Rectal Neoplasms
3
Nasopharyngeal Carcinoma
3
Multiple Myeloma
3
Mouth Neoplasms
3
Lymphoma, T-Cell
3
Lymphoma, B-Cell
3
Endometrial Neoplasms
3
Cholangiocarcinoma
3
Interventions
pembrolizumab
3
Paclitaxel
3
Doxorubicin
3
durvalumab
2
Standard of Care
2
Nivolumab
2
Ipilimumab
2
Ifosfamide
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
sintilimab
1
selinexor
1
sarilumab
1
regorafenib
1
pexidartinib
1
pertuzumab
1
peginterferon alfa-2a
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
eribulin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
Disulfides
×
1 year
×
Clear all
NCT04668300
2026-04-15
DOSa
M.D. Anderson Cancer Center
Phase 2
Active not recruiting
75 enrolled